In addition, AUT displayed a significant reduction in the activity of canonical and non-canonical NFκB signaling (Fig. 4E, and Fig. S9E), which has been shown to greatly impact tamoxifen resistance in breast cancer [115–117]. The gene discussed is NFKB1; the disease is breast cancer.